PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 8, 2012, Pages 1284-1288

  Ḧnscheid, Heribert ^a   Sweeney, Reinhart A ^a   Flentje, Michael ^a   Buck, Andreas K ^a   L̈hr, Mario ^a   Samnick, Samuel ^a   Kreissl, Michael ^a   Verburg, Frederik A ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

177Lu DOTATOC; Dosimetry; Meningioma; PRRT

Indexed keywords

GALLIUM 68; LUTETIUM 177; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSIMETRY; DRUG UPTAKE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MALE; MENINGIOMA; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PILOT STUDY; PROTEIN EXPRESSION; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOXEL BASED MORPHOMETRY; WHOLE BODY PET;

ADULT; AGED; BIOLOGICAL TRANSPORT; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; MALE; MENINGIOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84865466220     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2124-x     Document Type: Article

References (10)

1. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J Neurooncol. 2010;99:365-78.
2. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, et al. Peptide receptor radionuclide therapy with (90)YDOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1407-16.
3. Kwekkeboom DJ, De Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-30.
4. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, et al. PET imaging of somatostatin receptors using [68Ga]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42:1053-6. (Pubitemid 32595304)
5. Milker-Zabel S, Zabel-du BA, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOCPET. Int J Radiat Oncol Biol Phys. 2006;65:222-7.
6. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138-46.
7. Forrer F, Uusijarvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, et al. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1257-62. (Pubitemid 39222489)
8. Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, Goke B, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386-92. (Pubitemid 39361934)
9. Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864-70.
10. Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)] octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33:1346-51. (Pubitemid 44630791)